Hadiya's father formally joins BJP

Kasaragod, May 30: Karnataka origin IPS officer D Shilpa has been appointed the new Superintendent of Police of Kasargod district.

The 35-year-old 2016-batch IPS officer is the first woman SP of Kasaragod. 

Her appointment follows the sudden transfer of P S Sabu who was hitherto holding the post. He has now been appointed as SP of Alappuzha.

Shilpa has earlier served as ASP of Kasargod. She was also ASP of Kannur during the 2019 Lok Sabha elections.

Shilpa was one of the three IPS officers assigned to Kasaragod with IG Vijay Sakhare during the first phase of covid lockdown.

A native of HSR Layout in Bengaluru, Shilpa holds a Bachelor's degree in Electronics Engineering and a Masters Degree in Business Administration.

Mangaluru, July 10: Dakshina Kannada, which has emerged as one of the hotspots of covid-19 in Karnataka, has recorded at least six novel coronavirus related deaths in past 24 hours. 

According to sources, four people lost their battle with the novel coronavirus in Wenlock, the designated covid hospital. 

A 35-year-old man from Hosabettu, who was tested positive for COVID-19 recently, died at the Wenlock COVID hospital in the morning.

A 58-year-old woman from Thokkottu, a 67-year-old man from Ullal and a 65-year-old man from Falnir also passed away in the same hospital. 

Two other covid patients passed away in private hospitals. 

With this, the total number of death of covid patients in the district rose to 36. 

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.